A secondary RET mutation in the activation loop conferring resistance to vandetanib
Mechanisms of acquired resistance to RET tyrosine kinase inhibitors in lung cancers are largely unknown. Here, the authors report in a lung adenocarcinoma patient harboring a CCDC6-RET mutation in the RET kinase (S904F) that results in resistance to the kinase inhibitor vandetanib by increasing the...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2018-02-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-018-02994-7 |
| id |
doaj-5dda588c6b064bfcbe3ac0b3c008bd63 |
|---|---|
| record_format |
Article |
| spelling |
doaj-5dda588c6b064bfcbe3ac0b3c008bd632021-05-11T09:56:33ZengNature Publishing GroupNature Communications2041-17232018-02-01911910.1038/s41467-018-02994-7A secondary RET mutation in the activation loop conferring resistance to vandetanibTakashi Nakaoku0Takashi Kohno1Mitsugu Araki2Seiji Niho3Rakhee Chauhan4Phillip P. Knowles5Katsuya Tsuchihara6Shingo Matsumoto7Yoko Shimada8Sachiyo Mimaki9Genichiro Ishii10Hitoshi Ichikawa11Satoru Nagatoishi12Kouhei Tsumoto13Yasushi Okuno14Kiyotaka Yoh15Neil Q. McDonald16Koichi Goto17Division of Genome Biology, National Cancer Center Research InstituteDivision of Genome Biology, National Cancer Center Research InstituteAdvanced Institute for Computational Science, RIKENDepartment of Thoracic Oncology, National Cancer Center Hospital EastSignaling and Structural Biology Laboratory, The Francis Crick InstituteSignaling and Structural Biology Laboratory, The Francis Crick InstituteDivision of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer CenterDivision of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer CenterDivision of Genome Biology, National Cancer Center Research InstituteDivision of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer CenterDivision of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer CenterDivision of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer CenterMedical Proteomics Laboratory, Institute of Medical Science, The University of TokyoMedical Proteomics Laboratory, Institute of Medical Science, The University of TokyoDepartment of Clinical System Onco-Informatics, Graduate School of Medicine, Kyoto UniversityDepartment of Thoracic Oncology, National Cancer Center Hospital EastSignaling and Structural Biology Laboratory, The Francis Crick InstituteDepartment of Thoracic Oncology, National Cancer Center Hospital EastMechanisms of acquired resistance to RET tyrosine kinase inhibitors in lung cancers are largely unknown. Here, the authors report in a lung adenocarcinoma patient harboring a CCDC6-RET mutation in the RET kinase (S904F) that results in resistance to the kinase inhibitor vandetanib by increasing the ATP affinity and autophosphorylation activity of RET kinase.https://doi.org/10.1038/s41467-018-02994-7 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Takashi Nakaoku Takashi Kohno Mitsugu Araki Seiji Niho Rakhee Chauhan Phillip P. Knowles Katsuya Tsuchihara Shingo Matsumoto Yoko Shimada Sachiyo Mimaki Genichiro Ishii Hitoshi Ichikawa Satoru Nagatoishi Kouhei Tsumoto Yasushi Okuno Kiyotaka Yoh Neil Q. McDonald Koichi Goto |
| spellingShingle |
Takashi Nakaoku Takashi Kohno Mitsugu Araki Seiji Niho Rakhee Chauhan Phillip P. Knowles Katsuya Tsuchihara Shingo Matsumoto Yoko Shimada Sachiyo Mimaki Genichiro Ishii Hitoshi Ichikawa Satoru Nagatoishi Kouhei Tsumoto Yasushi Okuno Kiyotaka Yoh Neil Q. McDonald Koichi Goto A secondary RET mutation in the activation loop conferring resistance to vandetanib Nature Communications |
| author_facet |
Takashi Nakaoku Takashi Kohno Mitsugu Araki Seiji Niho Rakhee Chauhan Phillip P. Knowles Katsuya Tsuchihara Shingo Matsumoto Yoko Shimada Sachiyo Mimaki Genichiro Ishii Hitoshi Ichikawa Satoru Nagatoishi Kouhei Tsumoto Yasushi Okuno Kiyotaka Yoh Neil Q. McDonald Koichi Goto |
| author_sort |
Takashi Nakaoku |
| title |
A secondary RET mutation in the activation loop conferring resistance to vandetanib |
| title_short |
A secondary RET mutation in the activation loop conferring resistance to vandetanib |
| title_full |
A secondary RET mutation in the activation loop conferring resistance to vandetanib |
| title_fullStr |
A secondary RET mutation in the activation loop conferring resistance to vandetanib |
| title_full_unstemmed |
A secondary RET mutation in the activation loop conferring resistance to vandetanib |
| title_sort |
secondary ret mutation in the activation loop conferring resistance to vandetanib |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2018-02-01 |
| description |
Mechanisms of acquired resistance to RET tyrosine kinase inhibitors in lung cancers are largely unknown. Here, the authors report in a lung adenocarcinoma patient harboring a CCDC6-RET mutation in the RET kinase (S904F) that results in resistance to the kinase inhibitor vandetanib by increasing the ATP affinity and autophosphorylation activity of RET kinase. |
| url |
https://doi.org/10.1038/s41467-018-02994-7 |
| work_keys_str_mv |
AT takashinakaoku asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT takashikohno asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT mitsuguaraki asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT seijiniho asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT rakheechauhan asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT phillippknowles asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT katsuyatsuchihara asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT shingomatsumoto asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT yokoshimada asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT sachiyomimaki asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT genichiroishii asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT hitoshiichikawa asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT satorunagatoishi asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT kouheitsumoto asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT yasushiokuno asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT kiyotakayoh asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT neilqmcdonald asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT koichigoto asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT takashinakaoku secondaryretmutationintheactivationloopconferringresistancetovandetanib AT takashikohno secondaryretmutationintheactivationloopconferringresistancetovandetanib AT mitsuguaraki secondaryretmutationintheactivationloopconferringresistancetovandetanib AT seijiniho secondaryretmutationintheactivationloopconferringresistancetovandetanib AT rakheechauhan secondaryretmutationintheactivationloopconferringresistancetovandetanib AT phillippknowles secondaryretmutationintheactivationloopconferringresistancetovandetanib AT katsuyatsuchihara secondaryretmutationintheactivationloopconferringresistancetovandetanib AT shingomatsumoto secondaryretmutationintheactivationloopconferringresistancetovandetanib AT yokoshimada secondaryretmutationintheactivationloopconferringresistancetovandetanib AT sachiyomimaki secondaryretmutationintheactivationloopconferringresistancetovandetanib AT genichiroishii secondaryretmutationintheactivationloopconferringresistancetovandetanib AT hitoshiichikawa secondaryretmutationintheactivationloopconferringresistancetovandetanib AT satorunagatoishi secondaryretmutationintheactivationloopconferringresistancetovandetanib AT kouheitsumoto secondaryretmutationintheactivationloopconferringresistancetovandetanib AT yasushiokuno secondaryretmutationintheactivationloopconferringresistancetovandetanib AT kiyotakayoh secondaryretmutationintheactivationloopconferringresistancetovandetanib AT neilqmcdonald secondaryretmutationintheactivationloopconferringresistancetovandetanib AT koichigoto secondaryretmutationintheactivationloopconferringresistancetovandetanib |
| _version_ |
1721448940623101952 |